Skip to main content
. 2022 Jan 19;8(2):96. doi: 10.3390/jof8020096

Figure 2.

Figure 2

Cumulative 30-day survival of patients with severe COVID-19 fulfilling criteria of probable or possible COVID-19-associated Pulmonary Aspergillosis (CAPA) and patients without CAPA (Control) in the main study centre. Log rank p < 0.001.